Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute
pulmonary embolism. Important advances have enabled better understanding …

Background Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH)
therapy and balloon pulmonary angioplasty (BPA) are currently accepted therapies for …

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it
remains a life-shortening condition. There have been significant advances in imaging …

Background Treatment options for inoperable chronic thromboembolic pulmonary
hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor …

Pulmonary endarterectomy is the treatment of choice for patients with operable chronic
thromboembolic pulmonary hypertension (CTEPH) as it is potentially curative. In expert …

Background: Significant achievements in the treatment of chronic thromboembolic
pulmonary hypertension (CTEPH) have provided effective therapeutic options for most …

Background Women are more susceptible than men to several forms of pulmonary
hypertension, but have better survival. Sparse data are available on chronic thromboembolic …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a treatable form of pulmonary
hypertension and right heart failure. CTEPH (group 4 pulmonary hypertension) is caused by …

Background Recent studies have provided evidence for an important contribution of the
immune system in the pathophysiology of pulmonary arterial hypertension (PAH) and …